243 related articles for article (PubMed ID: 31381072)
1. The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk.
Di Dalmazi G; Fanelli F; Zavatta G; Ricci Bitti S; Mezzullo M; Repaci A; Pelusi C; Gambineri A; Altieri P; Mosconi C; Balacchi C; Golfieri R; Cosentino ER; Borghi C; Vicennati V; Pasquali R; Pagotto U
J Clin Endocrinol Metab; 2019 Nov; 104(11):5519-5528. PubMed ID: 31381072
[TBL] [Abstract][Full Text] [Related]
2. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
Araujo-Castro M; Hanzu FA; Pascual-Corrales E; García Cano AM; Marchan M; Escobar-Morreale HF; Valderrabano P; Casals G
Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
[TBL] [Abstract][Full Text] [Related]
3. Steroid Profiling by LC-MS/MS in Nonsecreting and Subclinical Cortisol-Secreting Adrenocortical Adenomas.
Di Dalmazi G; Fanelli F; Mezzullo M; Casadio E; Rinaldi E; Garelli S; Giampalma E; Mosconi C; Golfieri R; Vicennati V; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2015 Sep; 100(9):3529-38. PubMed ID: 26161451
[TBL] [Abstract][Full Text] [Related]
4. Steroidogenesis in patients with adrenal incidentalomas: Extended steroid profile measured by liquid chromatography-mass spectrometry after ACTH stimulation and dexamethasone suppression.
Huayllas MKP; Smith LM; Gallagher JC; Netzel BC; Singh RJ; Kater CE
Clin Endocrinol (Oxf); 2021 Jul; 95(1):29-40. PubMed ID: 33598999
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study.
Di Dalmazi G; Vicennati V; Pizzi C; Mosconi C; Tucci L; Balacchi C; Cosentino ER; Paolisso P; Fanelli F; Gambineri A; Pelusi C; Repaci A; Garelli S; Galiè N; Borghi C; Golfieri R; Pagotto U
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32413902
[TBL] [Abstract][Full Text] [Related]
6. Adrenal steroid metabolites and bone status in patients with adrenal incidentalomas and hypercortisolism.
Nakao H; Yokomoto-Umakoshi M; Nakatani K; Umakoshi H; Ogata M; Fukumoto T; Kaneko H; Iwahashi N; Fujita M; Ogasawara T; Matsuda Y; Sakamoto R; Izumi Y; Bamba T; Ogawa Y
EBioMedicine; 2023 Sep; 95():104733. PubMed ID: 37543511
[TBL] [Abstract][Full Text] [Related]
7. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; Cuesta Hernández M; Sampedro Núñez MA; Marazuela M
Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
[TBL] [Abstract][Full Text] [Related]
8. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
Araujo-Castro M; Parra Ramírez P; Martín Rojas-Marcos P; García Centeno R; Gracia Gimeno P; Tomé Fernández-Ladreda M; Sampedro Núñez MA; Higueruela C; Robles Lázaro C
Endocrine; 2023 Feb; 79(2):384-391. PubMed ID: 36261701
[TBL] [Abstract][Full Text] [Related]
9. Clinical course of patients with adrenal incidentalomas and cortisol autonomy: a German retrospective single center cohort study.
Remde H; Kranz S; Morell SM; Altieri B; Kroiss M; Detomas M; Fassnacht M; Deutschbein T
Front Endocrinol (Lausanne); 2023; 14():1123132. PubMed ID: 37223045
[TBL] [Abstract][Full Text] [Related]
10. Attenuation Value in Adrenal Incidentalomas: A Longitudinal Study.
Ceccato F; Tizianel I; Voltan G; Maggetto G; Merante Boschin I; Quaia E; Crimì F; Scaroni C
Front Endocrinol (Lausanne); 2021; 12():794197. PubMed ID: 34925247
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion.
Araujo-Castro M; García Cano A; Jiménez Mendiguchía L; Escobar-Morreale HF; Valderrábano P
Sci Rep; 2021 Oct; 11(1):20539. PubMed ID: 34654835
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas.
Sbardella E; Minnetti M; D'Aluisio D; Rizza L; Di Giorgio MR; Vinci F; Pofi R; Giannetta E; Venneri MA; Vestri A; Morelli S; Lenzi A; Isidori AM
Eur J Endocrinol; 2018 May; 178(5):501-511. PubMed ID: 29510982
[TBL] [Abstract][Full Text] [Related]
13. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
Araujo-Castro M; García Cano AM; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study.
Di Dalmazi G; Vicennati V; Garelli S; Casadio E; Rinaldi E; Giampalma E; Mosconi C; Golfieri R; Paccapelo A; Pagotto U; Pasquali R
Lancet Diabetes Endocrinol; 2014 May; 2(5):396-405. PubMed ID: 24795253
[TBL] [Abstract][Full Text] [Related]
15. First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.
Ceccato F; Antonelli G; Frigo AC; Regazzo D; Plebani M; Boscaro M; Scaroni C
J Endocrinol Invest; 2017 Jul; 40(7):753-760. PubMed ID: 28247215
[TBL] [Abstract][Full Text] [Related]
16. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study.
Di Dalmazi G; Vicennati V; Rinaldi E; Morselli-Labate AM; Giampalma E; Mosconi C; Pagotto U; Pasquali R
Eur J Endocrinol; 2012 Apr; 166(4):669-77. PubMed ID: 22267278
[TBL] [Abstract][Full Text] [Related]
17. Steroid content of the peripheral and adrenal vein in Cushing's syndrome due to adrenocortical adenoma and carcinoma.
Levine AC; Mitty HA; Gabrilove JL
J Urol; 1988 Jul; 140(1):11-5. PubMed ID: 2967899
[TBL] [Abstract][Full Text] [Related]
18. Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas.
Puglisi S; Leporati M; Amante E; Parisi A; Pia AR; Berchialla P; Terzolo M; Vincenti M; Reimondo G
Front Endocrinol (Lausanne); 2022; 13():833514. PubMed ID: 35222288
[TBL] [Abstract][Full Text] [Related]
19. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
Tsagarakis S; Roboti C; Kokkoris P; Vasiliou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
Araujo-Castro M; Parra Ramírez P; Robles Lázaro C; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2021 Dec; 20(4):735-744. PubMed ID: 34273083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
